Results 181 to 190 of about 79,537 (233)
Some of the next articles are maybe not open access.
Expression of ErbB-1 and ErbB-2 in meningioma
Journal of Clinical Neuroscience, 2010Meningiomas are benign intracranial tumours treated by neurosurgical resection. Residual or recurrent tumour may be treated with radiotherapy. Effective molecular therapy for residual and recurrent meningiomas is currently unavailable. We tested meningiomas for In-ErbB-1 and ErbB-2, and the levels were compared to normal brain, peripheral nerve ...
Agadha, Wickremesekera +2 more
openaire +2 more sources
Untangling the ErbB signalling network
Nature Reviews Molecular Cell Biology, 2001When epidermal growth factor and its relatives bind the ErbB family of receptors, they trigger a rich network of signalling pathways, culminating in responses ranging from cell division to death, motility to adhesion. The network is often dysregulated in cancer and lends credence to the mantra that molecular understanding yields clinical benefit: over ...
Yosef yarden
exaly +3 more sources
Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines
Cancer Immunology, Immunotherapy, 2002The tumour antigen ErbB-2 belongs to the epidermal growth factor receptor family. Numerous studies have shown that ErbB-2 is overexpressed in many cancers and it is prognostically important in a subset of malignancies. It is well recognised that this receptor has many characteristics that make it an excellent target for tumour-specific immunotherapy ...
Yip, Yum L., Ward, Robyn L.
openaire +3 more sources
Experimental Cell Research, 2009
Lung cancer remains the leading cause of cancer deaths worldwide, and advanced stage disease is largely refractory to conventional chemotherapy. Thus, there is an important need for alternative treatment strategies, and the ErbB proteins have emerged as potentially important therapeutic drug targets in this setting, apparently reflecting a state of ...
Sreenath V, Sharma, Jeffrey, Settleman
openaire +2 more sources
Lung cancer remains the leading cause of cancer deaths worldwide, and advanced stage disease is largely refractory to conventional chemotherapy. Thus, there is an important need for alternative treatment strategies, and the ErbB proteins have emerged as potentially important therapeutic drug targets in this setting, apparently reflecting a state of ...
Sreenath V, Sharma, Jeffrey, Settleman
openaire +2 more sources
Dominance of ErbB-1 Heterodimers in Lung Epithelial Cells Overexpressing ErbB-2
American Journal of Respiratory Cell and Molecular Biology, 1999This article examines differential expression and heterodimer formation of ErbB family members in tumorigenic and nontumorigenic human bronchial epithelial cells (HBECs). This cell system was developed previously as a model for lung adenocarcinoma by overexpression of c-erbB-2 in nontumorigenic, T antigen-immortalized HBECs.
A M, Fernandes +2 more
openaire +2 more sources
Science Signaling, 2000
Olayioye et al . have written a review on the ErbB receptors and their ligands. The review covers how receptor homo- and heterodimerization contribute to signaling complexity and specificity.
openaire +2 more sources
Olayioye et al . have written a review on the ErbB receptors and their ligands. The review covers how receptor homo- and heterodimerization contribute to signaling complexity and specificity.
openaire +2 more sources
Experimental Cell Research, 2003
Members of the ErbB (epidermal growth factor receptor) family of receptor tyrosine kinases are important in etiology of human mammary carcinoma, and are rational targets for cancer therapy. The frequent selection of ErbB2/HER2/Neu, and, less often, the epidermal growth factor receptor, and ErbB3 for overexpression in breast cancer implies that these ...
openaire +2 more sources
Members of the ErbB (epidermal growth factor receptor) family of receptor tyrosine kinases are important in etiology of human mammary carcinoma, and are rational targets for cancer therapy. The frequent selection of ErbB2/HER2/Neu, and, less often, the epidermal growth factor receptor, and ErbB3 for overexpression in breast cancer implies that these ...
openaire +2 more sources
Science Signaling, 2003
The ErbB family of receptor tyrosine kinases, which mediates the response to epidermal growth factor (EGF) and related peptides, contains four members: the EGF receptor (EGFR, ErbB1), ErbB2, ErbB3, and ErbB4. EGFR, ErbB3, and ErbB4 undergo ligand-dependent homo- or heterodimerization, which, together with their sensitivity to multiple ...
openaire +2 more sources
The ErbB family of receptor tyrosine kinases, which mediates the response to epidermal growth factor (EGF) and related peptides, contains four members: the EGF receptor (EGFR, ErbB1), ErbB2, ErbB3, and ErbB4. EGFR, ErbB3, and ErbB4 undergo ligand-dependent homo- or heterodimerization, which, together with their sensitivity to multiple ...
openaire +2 more sources